33106-64-8Relevant articles and documents
Synthesis of a new asymmetric cyclopentadienyl ligand: application to the preparation of a trivalent samarium complex
Weghe, P. Van de,Bied, C.,Collin, J.,Marcalo, J.,Santos, I.
, p. 121 - 126 (1994)
A short synthesis of a new asymmetric cyclopentadienyl ligand 2 (Cp'H) substituted by a benzyl ether group in the β position on the side chain of the ring is described.Reaction of its potassium salt with samarium triiodide leads to the isolation of a triv
Preparation of Optically Active (S)-2-(Benzyloxy)propanal
Varelis, Peter,Johnson, Brian L.
, p. 1775 - 1780 (1995)
A convenient and large scale amenable preparation of optically active ethyl (S)-2-(benzyloxy)propionate (5) from ethyl (S)-lactate (4), and the conversion of the ester (5) by two alternative methods into (S)-2-(benzyloxy)propanal (1) are described.
Benzoxaborole Catalyst for Site-Selective Modification of Polyols
Kusano, Shuhei,Miyamoto, Shoto,Matsuoka, Aki,Yamada, Yuji,Ishikawa, Ryuta,Hayashida, Osamu
supporting information, p. 1598 - 1602 (2020/02/11)
The site-selective modification of polyols bearing several hydroxyl groups without the use of protecting groups remains a significant challenge in synthetic chemistry. To address this problem, novel benzoxaborole derivatives were designed as efficient catalysts for the highly site-selective and protecting-group-free modification of polyols. To identify the effective substituent groups enhancing the catalytic activity and selectivity, a series of benzoxaborole catalysts 1a–k were synthesized. In-depth analysis for the substituent effect revealed that 1i–k, bearing multiple electron-withdrawing fluoro- and trifluoromethyl groups, exhibited the greatest catalytic activity and selectivity. Moreover, 1i-catalyzed benzoylation, tosylation, benzylation, and glycosylation of various cis-1,2-diol derivatives proceeded with good yield and site-selective manner.
COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF PAIN, INFLAMMATION AND/OR AUTOIMMUNITY
-
Page/Page column 15-16, (2020/08/13)
The present invention relates to a polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl- 4-hydroxybenzene)-3-phenylpropylamide or synonymously named N-[2-(4-Hydroxy-phenyl)- -(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and to the treatment